HC Wainwright Lowers Earnings Estimates for Scholar Rock

Key Points

• HC Wainwright lowered Scholar Rock’s FY2026 EPS estimate to a loss of $3.30 from $3.29, while maintaining a “Buy” rating and a $70 price target.
• Analyst sentiment remains broadly positive: Scholar Rock has a “Moderate Buy” consensus rating and an average target price of $66, with several firms recently raising their targets.
• Scholar Rock shares opened at $49.37, within a 12-month range of $27.07 to $61.76. The company reported quarterly EPS of ($0.84), matching consensus estimates, while institutional investors own 91.08% of its stock.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for Scholar Rock in a research note issued on Tuesday, September 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($3.30) for the year, down from their previous estimate of ($3.29). HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($3.23) per share. HC Wainwright also issued estimates for Scholar Rock's FY2027 earnings at ($1.95) EPS, FY2028 earnings at ($0.59) EPS, FY2029 earnings at $0.47 EPS and FY2030 earnings at $1.44 EPS.

Several other equities research analysts also recently issued reports on the stock. Citigroup raised their price objective on shares of Scholar Rock from $60.00 to $74.00 and gave the stock a "buy" rating in a research note on Monday. Jefferies Financial Group increased their target price on shares of Scholar Rock from $57.00 to $65.00 and gave the company a "buy" rating in a research note on Monday. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $56.00 to $63.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. UBS Group reaffirmed a "buy" rating on shares of Scholar Rock in a report on Tuesday. Finally, Truist Financial reiterated a "buy" rating and issued a $76.00 target price (up from $55.00) on shares of Scholar Rock in a research note on Monday. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $66.00.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $49.37 on Thursday. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The business's 50 day moving average is $53.22 and its two-hundred day moving average is $49.62. The company has a market cap of $6.01 billion, a P/E ratio of -14.31 and a beta of 0.67. Scholar Rock has a 12 month low of $27.07 and a 12 month high of $61.76.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.84) earnings per share for the quarter, hitting the consensus estimate of ($0.84). During the same period last year, the firm posted ($0.98) EPS.

Insider Buying and Selling

In related news, Director Joshua Reed sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the completion of the sale, the director owned 19,518 shares of the company's stock, valued at approximately $1,048,897.32. This trade represents a 13.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the transaction, the director owned 27,856 shares in the company, valued at approximately $1,500,881.28. This trade represents a 9.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 17,149 shares of company stock valued at $923,108 in the last quarter. Corporate insiders own 10.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC raised its stake in shares of Scholar Rock by 20.8% in the second quarter. GAMMA Investing LLC now owns 1,406 shares of the company's stock worth $77,000 after purchasing an additional 242 shares during the last quarter. Values First Advisors Inc. boosted its holdings in Scholar Rock by 1.5% in the first quarter. Values First Advisors Inc. now owns 18,850 shares of the company's stock worth $927,000 after purchasing an additional 286 shares during the last quarter. IFP Advisors Inc grew its position in Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company's stock worth $27,000 after purchasing an additional 450 shares during the period. EverSource Wealth Advisors LLC raised its stake in Scholar Rock by 151.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company's stock valued at $38,000 after buying an additional 525 shares during the last quarter. Finally, Syon Capital LLC lifted its holdings in shares of Scholar Rock by 6.4% during the 2nd quarter. Syon Capital LLC now owns 9,782 shares of the company's stock valued at $538,000 after buying an additional 588 shares during the period. Institutional investors own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock, Inc is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company's approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.

Scholar Rock's lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.